09:20 AM EST, 02/28/2025 (MT Newswires) -- US stocks looked set to open higher Friday as investors parsed key inflation data that matched analyst forecasts.

Dow Jones Industrial Average futures were up 0.49%, S&P 500 futures gained 0.29%, and Nasdaq futures edged 0.10% higher.

Oil prices were moving lower, with front-month global benchmarks Brent crude and West Texas Intermediate crude declining 1.05% and 1.21% respectively.

The January core personal consumption price index slowed to an annual rate of 2.6% from 2.9% the previous month, meeting analyst forecasts, according to Bloomberg. The monthly core PCE prince index rose by 0.3% in January from 0.2% in December, also as expected.

In other world markets, Japan's Nikkei tumbled 2.88%, Hong Kong's Hang Seng plummeted 3.28%, and China's Shanghai Composite fell 1.98%. In Europe's early afternoon session, the UK's FTSE 100 was up 0.38%, while Germany's DAX and France's CAC 40 dropped 0.51% and 0.46%, respectively.

Among gaining stocks, Interactive Strength ( TRNR ) jumped 32%, adding to a 22% gain on Thursday. BioXcel Therapeutics ( BTAI ) gained 17% after it said Friday that it has regained compliance with Nasdaq's minimum closing bid price requirement. OneConnect Financial Technology ( OCFT ) advanced 18% after a 4% loss the previous session. And Organogenesis ( ORGO ) shares climbed 18%, after a 5.5% loss on Thursday.

On the losing side, shares of DocGo ( DCGO ) tumbled 22% after Deutsche Bank downgraded the company's stock Friday to hold from buy, and lowered its price target to $2.85 From $5. Mustang Bio ( MBIO ) dropped 26% after it said after hours on Thursday that it has exited the lease for its manufacturing facility in Worcester, Massachusetts and divested certain fixed assets. Iovance Biotherapeutics ( IOVA ) shares dropped 23% after losing 1.7% on Thursday. DLocal ( DLO ) shed 25% after it reported late Thursday that its Q4 earnings and revenue missed analyst forecasts. And NetApp ( NTAP ) shares were down 17%, after reporting late Thursday lower fiscal Q3 non-GAAP earnings and cutting its fiscal 2025 non-GAAP EPS guidance.